Business Wire

GALDERMA

Share
Galderma Takes the ‘Face of Cetaphil®’ to the Runway at New York Fashion Week

Cetaphil®, a leading dermatologist-recommended sensitive skincare brand, is launching a first-of-its-kind global skincare immersion. This immersion will put the sensitive skin science behind its formulas to the ‘ultimate skin stress test’ at New York Fashion Week (NYFW).

As an extension of the brand’s ‘We Do Skin, You Do You’ campaign, Cetaphil’s NYFW activation will enlist influencers and consumers from 14 different countries to be the ‘Face of Cetaphil.’ They will have entered a global contest to win a trip to New York City, where they will act as on-the-ground correspondents alongside other influencers. The delegates will participate in 48 hours of Fashion Week events and activations putting Cetaphil’s sensitive skincare formulas to the test.

 

“In 2022, we debuted the global ‘We Do Skin. You Do You’ campaign to help empower those with sensitive skin to do more of the things they love – without hesitation. This year, with the ‘Face of Cetaphil,’ we are bringing the campaign to life by tapping into a cultural moment that is very relevant to our consumers. New York Fashion Week is the perfect place to put the brand at the forefront of where fashion, beauty and skincare intersect.”

 

GERRY MUHLE
HEAD OF GLOBAL PRODUCT STRATEGY
GALDERMA

 

 

The initiative includes partnerships with contemporary fashion brand Alice + Olivia, modeling and talent agency Wilhelmina International Inc. and global fashion and media brand, Highsnobiety. The competition winners will be joined by sensitive skin expert Dr. Lindsey Zubritsky, board-certified dermatologist at Premier Dermatology and Skin Cancer Center in Ocean Springs, Mississippi, U.S.

 

“Some cosmetics are a main trigger of sensitive skin, due to the inclusion of potentially irritating ingredients and regular usage. Similarly for clothing, when fabrics interact with skin that has an interrupted skin barrier, products can lead to irritated skin or skin conditions such as contact dermatitis. Scientific research is foundational to everything Cetaphil does, and research has shown that sensitive skin needs extra care. Cetaphil products can help restore and rebuild the skin moisture barrier, helping to reduce skin aggravation. This ultimately helps people feel comfortable in their own skin – and in their beauty and fashion looks.”

 

DR. LINDSEY ZUBRITSKY
BOARD-CERTIFIED DERMATOLOGIST
PREMIER DERMATOLOGY AND SKIN CANCER CENTER, OCEAN SPRINGS, MD

 

 

As Alice + Olivia’s exclusive skincare sponsor, Cetaphil will have a strong presence backstage at one of Fashion Week’s hottest shows. The partnership will include a ‘skincare prep’ area where models will have the opportunity to meet with a Cetaphil skin expert and have their skin prepped using Cetaphil products. These include the Gentle Skin Cleanser, Healthy Renew Face Serum and Moisturizing Lotion, which ensure a hydrated canvas for makeup and clothing application.

 

“Over many NYFW seasons, I’ve learned how important a great skincare routine is to make up for the long hours and lack of sleep that go into making our beautiful shows a reality. We’re so excited to partner with Cetaphil this season as our skincare sponsor. Glowing skin is the ultimate accessory, and their products work magic to protect and hydrate.”

 

STACEY BENDET
CEO AND CREATIVE DIRECTOR
ALICE + OLIVIA

 

 

Through Cetaphil’s partnership with Wilhelmina Modeling Agency, attendees will also get exclusive access to a group of models who are walking in NYFW shows. These experiential, behind-the-scenes moments will give them an insider’s look at Fashion Week, seeing how it impacts skin, through the eyes of a model.

A Cetaphil x Highsnobiety pop-up will take place on Saturday, February 10 from 11:00 AM to 6:00 PM. The space will serve as a fashion-forward sensitive skin sanctuary where New Yorkers can relax and refuel amidst the hustle and bustle of Fashion Week. The pop-up will be completed with skin consultations, beauty services, custom hydrating beverages and more.

To follow the Face of Cetaphil throughout NYFW, check out your country’s Cetaphil handles on Instagram and TikTok. The brand will be sharing content across its channels.

About Cetaphil

Seventy-five years ago, a leading pharmacist created the first Cetaphil product – a gentle, yet powerful formula to clean without stripping and moisturize without clogging. Today, Cetaphil is dermatologist-recommended for sensitive skin and recognized around the world. With the help of leading skincare experts, Cetaphil continues to develop innovative skincare technologies for sensitive skin that help restore, protect and maintain skin’s health every day. For more information, visit www.cetaphil.com.

About Galderma

Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240207631228/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye